The Effect of Subcutaneous Injection of Unfractionated and Low Molecular Weight Heparin on Thrombin Generation in Platelet Rich Plasma - A Study in Human Volunteers

A Vicky Bendetowicz; Hu Kai; Richard Knebel; H Caplain; H Coenraad Hemker; Theo Lindhout; Suzette Béguin

doi:10.1055/s-0038-1648946

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1994; 72(05): 705-712
DOI: 10.1055/s-0038-1648946

Original Article

Schattauer GmbH Stuttgart

The Effect of Subcutaneous Injection of Unfractionated and Low Molecular Weight Heparin on Thrombin Generation in Platelet Rich Plasma - A Study in Human Volunteers

A Vicky Bendetowicz

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

,

Hu Kai

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

,

Richard Knebel

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

,

H Caplain

²Institut Aster, Paris, France

,

H Coenraad Hemker

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

,

Theo Lindhout

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

,

Suzette Béguin

¹The Department of Biochemistry, Cardiovascular Research Institute Maastricht and University of Limburg, Maastricht, The Netherlands

› Institutsangaben

Abstract

als PDF herunterladen

Summary

We administered a dose of unfractionated heparin (UFH) and two doses of a low molecular weight heparin (LMWH) to healthy volunteers by SC injection. The doses given were: a) UFH, 5000IU, which represents 8.7 mg of >5,400 MW active heparin (ACLM) and no <5,400 active heparin (BCLM), b) enoxaparin 40 mg (3.4 mg ACLM, 2.2 mg BCLM) and c) enoxaparin 1 mg/kg body weight (on the mean 75 mg, containing 6.4 mg ACLM and 4.1 mg BCLM). We determined the effect on thrombin generation in platelet rich plasma (PRP) between 1 and 8 h after injection. UFH administration caused only a 5-8% inhibition of the thrombin potential (i. e. the area under the thrombin generation curve). Significantly higher inhibition of the thrombin potential was seen after administration of both doses of enoxaparin. To wit 9-26% at the low dose and 29-46% at the high dose. UFH injection caused a prolongation of the lag-time before the thrombin burst. Only with the high dose of enoxaparin the lag-times were significantly more prolonged with enoxaparin than with UFH.

Excess amounts of platelet factor 4 (PF4) were able to neutralize completely the anti-thrombin activity in normal plasma spiked with enoxaparin as well as in plasma samples obtained after SC enoxaparin injection. With a large excess of PF4 the anti-factor Xa activity could be inhibited to a maximum of 50%. This indicates that ACLM (above critical length material, MW >5400) is neutralized completely by PF4 whereas BCLM (below critical length material, MW <5400) is not. The anti-thrombin heparin-activity, hence the ACLM fraction of heparin, was shown to have disappeared from the serum of PRP samples. The BCLM fraction was found after coagulation of PRP in concentrations that were indistinguishable from those in the PPP.

We conclude that in PRP the activity of the BCLM fraction of injected LMWH remains after platelet activation. The possible role of this activity in thrombin inhibition and in the antithrombotic action of low molecular weight heparins is discussed.

PDF (638 kb)

Referenzen

References
1 Hirsh J. Low molecular weight heparin. Thromb Haemost 1993; 70: 204-207
2 Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. J Wiley & Sons; Chichester: 1992
3 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulfate, low molecular weight heparin and pentosan poly sulfate. Br J Haematol 1985; 60: 695-704
4 Ofosu FA, Sié P, Modi GJ, Fernandez F, Buchanan M, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. BiochemJ 1987; 243: 579-88
5 Hemker HC. The mode of action of heparin in plasma. In: Xlth Congr Thromb Haemostas Verstraete M, Vermylen J, Lijnen HR, Arnout J. eds. I. S. T. H. and Leuven University Press; 1987: 17-36
6 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462
7 Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401
8 Hemker HC, Béguin S. Mode of action of unfractionated and low molecular weight heparin on the generation of thrombin in plasma. Haemostasis 1990; 20 (Suppll) 81-92
9 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma. Its inhibition by heparin. Thromb Haemost 1989; 61: 25-9
10 Béguin S, Wielders S, Lormeau CJ, Hemker HC. The mode of action of CY 216 and CY 222 in plasma. Thromb Haemost 1991; 67: 33-41
11 Wu VY, McCoy LE. Platelet factor 3: Quantitation and characterization. Thromb Res 1977; 11: 581-593
12 Levine SP, Wohl H. Human platelet factor 4: Purification and characterisation by affinity chromatography. J Biol Chem 1976; 251: 324-328
13 Lane DA, Denton J, Flynn A, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
14 Niewiarowsky S, Rucinsky B, James P, Lindahl U. Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule. FEBS letters 1979; 102: 75
15 Denton J, Lane DJ, Thunberg L, Slater AM, Lindhal U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-60
16 Michalski RLane DA, Pepper DS, Kakkar VV. Neutralization of heparin in plasma by platelet factor 4 and protamine sulphate. Br J Haematol 1978; 38: 561-571
17 Schoen P, Lindhout T, Franssen J, Hemker HC. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombinIII. Effect of platelet factor 4. Thromb Haemost 1991; 66: 435-41
18 Bendetowicz AV, Pacaud E, Béguin S, Uzan A, Hemker HC. On the relationship between molecular mass and anticoagulant activity of a low molecular weight heparin (enoxaparin). Thromb Haemost 1992; 67: 556-562
19 Bendetowicz A-V, Béguin S, Caplain H, Hemker HC. Pharmacokinetics of a low molecular weight heparin (enoxaparin) after subcutaneous injection,comparison with unfractionated heparin. A three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-313
20 Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452
21 Mertens K, Bertina R. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
22 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
23 Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and the presence of platelet factor 4 (PF4). British J Haemat 1992; 82: 406-13
24 Béguin S, Hemker HC. Mode of action of enoxaparin in plasma. Acta Chir Scand Suppl 1990; 556: 51-6
25 Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and Thrombosis. Bloom A, Thomas D. eds Edinburgh; Churchill Livingstone: 1994: 477-490
26 Mattson CH, Palm M, Soderberg K, Holmer E. Antithrombotic effects of heparin oligosaccharides. Proc New York Acad Sci 1989; 556: 323-332
27 Gray E, Padilla A, Barrowcliffe TW. Antithrombotic activity and its relationship to in vitro anticoagulant effects. Haemostasis 1993; 23 (Suppl. 01) 99-102
28 Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): Comparison with standard heparin. J Clin Med 1989; 114: 349-357
29 Amar J, Caranobe C, Petitou M, Sié P, Boneu B. Antithrombotic properties of heparins in relation to their anti-factor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990; 76: 94-100
30 Carrie D, Caranobe C, Boneu B. A comparison of the antithrombotic effects of heparin and of a low molecular weight heparin with increasing anti-factor Xa/antifactor Ha ratio in the rabbit. Br J Haematol 1993; 83: 622-626
31 Peyrou V, Lormeau JC, Caranobe C, Gabaig AM, Crepon B, Saivin S, Houin G, Sié P, Boneu B. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb Haemost 1994; 72: 268-74
32 Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model. Thrombosis Research 1991; 64: 405-12
33 Heras M, Chesebro JH, Penny W, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet thrombus deposition during angioplasty in pigs; heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65
34 Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994; 24: 69-80